{"disease":{"id":"myeldysplastic-syndrome-mds","name":"myeldysplastic syndrome mds"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07396480","title":"Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":186,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT07528417","title":"Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":75,"lead_sponsor_name":"University of Manitoba","has_results":false},{"nct_id":"NCT01629082","title":"Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}